<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04521959</url>
  </required_header>
  <id_info>
    <org_study_id>istanbul medipol university</org_study_id>
    <nct_id>NCT04521959</nct_id>
  </id_info>
  <brief_title>Blood Flow Restricted Exercise in Chronic Obstructive Pulmonary Disease</brief_title>
  <acronym>COPD</acronym>
  <official_title>The Effect of Resistance and Aerobic Exercises With Blood Flow Restricted in COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medipol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medipol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic obstructive pulmonary disease (COPD) classified by a pulmonologist in&#xD;
      accordance with the GOLD criteria will be randomly divided into 2 groups.&#xD;
&#xD;
      The first group (n = 25) was accompanied by blood flow restriction (CAC), 3 times a week, 8&#xD;
      weeks, 1RMx 30% intensity, 10 repetitions, 3 sets, 30 seconds rest interval, progressive&#xD;
      resistance exercise (PRE) and after 5 minutes of rest by cycling. Progressive aerobic&#xD;
      exercise (AE) (BFR PRE + AE group) in the target heart rate range of 40-80% intensity will be&#xD;
      applied to the second group (n = 25), PRE and AE (PRE + AE group) performed at the same&#xD;
      intensity and duration without BFR.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Determination of application groups: Patients with chronic obstructive pulmonary disease&#xD;
      (COPD) classified by a pulmonologist in accordance with the GOLD criteria will be randomly&#xD;
      divided into 2 groups and application groups will be determined.&#xD;
&#xD;
      Applications to be made:&#xD;
&#xD;
      The first group (n = 25) accompanied by CAC; Progressive resistance exercise (DE) 3 times a&#xD;
      week, 1RMx 30% intensity, 10 repetitions, 3 sets, 30 seconds rest interval, and cycling after&#xD;
      5 minutes rest, progressive aerobic exercise in the target heart rate range of 40-80%&#xD;
      intensity (AE ) (KAK DE + AE group) will be applied.&#xD;
&#xD;
      To the second group (n = 25) without CAC; 3 times a week, 8 weeks, 1RMx 30% intensity, 10&#xD;
      repetitions, 3 sets, 30 seconds of rest interval, and after 5 minutes of rest, AE (DE + AE&#xD;
      group) will be applied in the target heart rate range of 40-80%, which is done by cycling.&#xD;
&#xD;
      Calculation of 1RM: Epley formula will be used in the calculation. According to this; 1 RM =&#xD;
      (1 + .0333 x number of repetitions) x weight removed.&#xD;
&#xD;
      Progress in resistance exercise; According to the modified borg scale (MBS), the amount of&#xD;
      the lifted weight calculated on the basis of the increase in the 1RM value measured in every&#xD;
      three consecutive sessions will be provided by increasing the amount of weight, on the&#xD;
      condition that it remains between 4-6 intensity.&#xD;
&#xD;
      This too; It will be calculated from the formula &quot;Target heart rate = (Maximal heart&#xD;
      rate-resting heart rate) x% desired intensity ratio + resting heart rate&quot;.&#xD;
&#xD;
      The target occlusion amount in the lower extremity will be calculated by calculating 45% of&#xD;
      the complete occlusion rates reported by Michael et al. The proximal border of the thigh&#xD;
      cuffs in the CAC group will be tied at the level of the gluteal lines on both sides.&#xD;
&#xD;
      Exercise tolerance and dyspnea condition; Measurement properties in COPD will be evaluated&#xD;
      using a modified Borg scale (MBS), which has well-defined characteristics. Individuals will&#xD;
      use bronchodilators approved by their physician before each trial and continue drug therapy&#xD;
      throughout the study.&#xD;
&#xD;
      The target aerobic exercise intensity will be reached in the last minute of the first&#xD;
      five-minute warm-up period by maintaining a 4-6 feeling of dyspnea in the MBS, by increasing&#xD;
      pedal resistance and speed. The intensity increase will be increased by 5% for each&#xD;
      subsequent session and the target heart rate will be limited to 80%. In case of extreme&#xD;
      shortness of breath, the intensity of exercise will be reduced down to the resting heart&#xD;
      rate.&#xD;
&#xD;
      In case of oxygen desaturation (85%) during interventions, the intervention will be suspended&#xD;
      until the next session.&#xD;
&#xD;
      Aerobic exercise study protocol: warm-up at 50 RPM speed and lowest pedal resistance for the&#xD;
      first 4 minutes, reaching the target exercise intensity range in the next 1 min, aerobic&#xD;
      training at the target heart rate range and appropriate MBS for the next 20 minutes, the last&#xD;
      5 minutes It will be applied in the form of cooling. The duration will be reduced in case of&#xD;
      extreme shortness of breath, fatigue and muscle pain due to increased exercise volume. The&#xD;
      distance, calories, and maximum speed values measured during the first, 9 and 24 sessions&#xD;
      will be recorded.&#xD;
&#xD;
      Before the study and at the end of the 8th week, oxidative stress markers (plasma protein&#xD;
      carbonyl concentration, lipid hydroperoxides, total antioxidant capacity (TAK)), muscle&#xD;
      damage status (creatine phosphokinase, myoglobin), anti-inflammatory response (interleukin 6&#xD;
      (IL-6), risk of venous thromboembolism and thrombus formation (D-dimer, thrombin-antithrombin&#xD;
      3 component (TAT), c-reactive protein (CRP), fibrinogen), body mass index, respiratory&#xD;
      function tests (FEV1, FVC), oxygen saturation and heart rate ( pulse oximetry), six-minute&#xD;
      walking test, and quality of life (SF-36) will be evaluated at least 6 hours prior to taking&#xD;
      medication.&#xD;
&#xD;
      The change in the quadriceps muscle mass will be examined by a radiologist who is not&#xD;
      involved in the study, by measuring the transverse and anteroposterior lengths of the&#xD;
      relevant muscle using Toshiba aplio 300 brand ultrasound device.&#xD;
&#xD;
      Statistical evaluation of results: Paired t-test, repeated measurement analysis of variables&#xD;
      (RMANOVA), Kolmogorov-Smirnov test, post hoc contrast analysis, bonferroni correction will be&#xD;
      used in the statistical analysis of intervention results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Anticipated">April 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 27, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two randomized controlled intervention groups will be formed.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>50 COPD patients will be divided into two equal groups according to age, gender and disease severity.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1/FVC rate</measure>
    <time_frame>eight weeks</time_frame>
    <description>respiratory function test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>creatine kinase</measure>
    <time_frame>eight weeks</time_frame>
    <description>muscle breakdown marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>c reactive protein</measure>
    <time_frame>eight weeks</time_frame>
    <description>thrombus formation risk marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>d-dimer</measure>
    <time_frame>eight weeks</time_frame>
    <description>venous thromboembolism marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>total antioxidant status</measure>
    <time_frame>eight weeks</time_frame>
    <description>oxidative stress marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>total oxidant status</measure>
    <time_frame>eight weeks</time_frame>
    <description>oxidative stress marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>interleukin 6</measure>
    <time_frame>eight weeks</time_frame>
    <description>inflammation marker</description>
  </primary_outcome>
  <primary_outcome>
    <measure>oxygen saturation</measure>
    <time_frame>three times a week</time_frame>
    <description>blood gas test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>heart rate</measure>
    <time_frame>three times a week</time_frame>
    <description>for exercise dose determination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>six minute walk test</measure>
    <time_frame>eight weeks</time_frame>
    <description>strength evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ST george's respiratory questionnaire</measure>
    <time_frame>eight weeks</time_frame>
    <description>used to evaluate the effects of respiratory disease's symptoms and illness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>quadriceps muscle diameter</measure>
    <time_frame>eight weeks</time_frame>
    <description>Measurement of change in muscle volume</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Copd</condition>
  <arm_group>
    <arm_group_label>Blood Flow Restricted Aerobic and Resistance Exercise Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>kan akımı kısıtlanarak.direnç ve bisikletle aerobik egzersiz uygulanacak</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal aerobik ve direnç egzersiz grubu</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normal şartlarda aerobik ve direnç egzersizi uygulanacak</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood flow restricted and normal aerobic exercise and resistance exercise</intervention_name>
    <description>Interventions of the same duration and intensity will be applied to two groups.</description>
    <arm_group_label>Blood Flow Restricted Aerobic and Resistance Exercise Group</arm_group_label>
    <arm_group_label>Normal aerobik ve direnç egzersiz grubu</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Being diagnosed with mild to severe COPD according to GOLD criteria in the age range&#xD;
             of 40-78&#xD;
&#xD;
          -  No drug change for at least 30 days&#xD;
&#xD;
          -  Not participating in a structured activity program for at least six months&#xD;
&#xD;
          -  Have the ability to cooperate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of any pathology that limits physical activity performance&#xD;
&#xD;
          -  Presence of severe or unstable heart disease&#xD;
&#xD;
          -  Presence of peripheral artery disease&#xD;
&#xD;
          -  Being in an exacerbation period of the disease&#xD;
&#xD;
          -  Presence of another active disease (rheumatic, oncological, traumatic etc.)&#xD;
&#xD;
          -  Any neurological or orthopedic disease that prevents exercise&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Since COPD affects male gender more, the number of male patients participating in the intervention is higher than female patients.</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Karabük Üniversitesi Araştırma Hastanesi Göğüs Hastalıkları Kliniği</name>
      <address>
        <city>Karabük</city>
        <zip>78600</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Berzosa C, Cebrián I, Fuentes-Broto L, Gómez-Trullén E, Piedrafita E, Martínez-Ballarín E, López-Pingarrón L, Reiter RJ, García JJ. Acute exercise increases plasma total antioxidant status and antioxidant enzyme activities in untrained men. J Biomed Biotechnol. 2011;2011:540458. doi: 10.1155/2011/540458. Epub 2011 Mar 9.</citation>
    <PMID>21436993</PMID>
  </reference>
  <results_reference>
    <citation>Patterson SD, Hughes L, Warmington S, Burr J, Scott BR, Owens J, Abe T, Nielsen JL, Libardi CA, Laurentino G, Neto GR, Brandner C, Martin-Hernandez J, Loenneke J. Blood Flow Restriction Exercise: Considerations of Methodology, Application, and Safety. Front Physiol. 2019 May 15;10:533. doi: 10.3389/fphys.2019.00533. eCollection 2019. Review. Erratum in: Front Physiol. 2019 Oct 22;10:1332.</citation>
    <PMID>31156448</PMID>
  </results_reference>
  <results_reference>
    <citation>Nolan CM, Rochester CL. Exercise Training Modalities for People with Chronic Obstructive Pulmonary Disease. COPD. 2019 Dec;16(5-6):378-389. doi: 10.1080/15412555.2019.1637834. Epub 2019 Nov 4. Review.</citation>
    <PMID>31684769</PMID>
  </results_reference>
  <results_reference>
    <citation>Scott BR, Loenneke JP, Slattery KM, Dascombe BJ. Exercise with blood flow restriction: an updated evidence-based approach for enhanced muscular development. Sports Med. 2015 Mar;45(3):313-25. doi: 10.1007/s40279-014-0288-1. Review.</citation>
    <PMID>25430600</PMID>
  </results_reference>
  <results_reference>
    <citation>Kacin A, Strazar K. Frequent low-load ischemic resistance exercise to failure enhances muscle oxygen delivery and endurance capacity. Scand J Med Sci Sports. 2011 Dec;21(6):e231-41. doi: 10.1111/j.1600-0838.2010.01260.x. Epub 2011 Mar 8.</citation>
    <PMID>21385216</PMID>
  </results_reference>
  <results_reference>
    <citation>Loenneke JP, Allen KM, Mouser JG, Thiebaud RS, Kim D, Abe T, Bemben MG. Blood flow restriction in the upper and lower limbs is predicted by limb circumference and systolic blood pressure. Eur J Appl Physiol. 2015 Feb;115(2):397-405. doi: 10.1007/s00421-014-3030-7. Epub 2014 Oct 22.</citation>
    <PMID>25338316</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilson JM, Lowery RP, Joy JM, Loenneke JP, Naimo MA. Practical blood flow restriction training increases acute determinants of hypertrophy without increasing indices of muscle damage. J Strength Cond Res. 2013 Nov;27(11):3068-75. doi: 10.1519/JSC.0b013e31828a1ffa.</citation>
    <PMID>23446173</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilk M, Krzysztofik M, Gepfert M, Poprzecki S, Gołaś A, Maszczyk A. Technical and Training Related Aspects of Resistance Training Using Blood Flow Restriction in Competitive Sport - A Review. J Hum Kinet. 2018 Dec 31;65:249-260. doi: 10.2478/hukin-2018-0101. eCollection 2018 Dec.</citation>
    <PMID>30687436</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>December 27, 2020</last_update_submitted>
  <last_update_submitted_qc>December 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medipol University</investigator_affiliation>
    <investigator_full_name>Ahmet Gunes</investigator_full_name>
    <investigator_title>PhD Student</investigator_title>
  </responsible_party>
  <keyword>COPD, blood flow restriction, exercise</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

